Last reviewed · How we verify
zonisamide high dose group
zonisamide high dose group is a Sulfonamide anticonvulsant Small molecule drug developed by Eisai Korea Inc.. It is currently FDA-approved for Epilepsy (adjunctive therapy for partial seizures), Generalized tonic-clonic seizures.
Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability by blocking sodium and calcium channels and enhancing GABAergic inhibition.
Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability by blocking sodium and calcium channels and enhancing GABAergic inhibition. Used for Epilepsy (adjunctive therapy for partial seizures), Generalized tonic-clonic seizures.
At a glance
| Generic name | zonisamide high dose group |
|---|---|
| Sponsor | Eisai Korea Inc. |
| Drug class | Sulfonamide anticonvulsant |
| Target | Voltage-gated sodium channels, T-type calcium channels, GABA enhancement |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Zonisamide works through multiple mechanisms: it blocks voltage-gated sodium channels to reduce repetitive neuronal firing, inhibits T-type calcium channels, and enhances the activity of GABA, the brain's primary inhibitory neurotransmitter. These combined effects suppress abnormal electrical activity in the brain, making it effective for seizure control. The high-dose formulation delivers increased drug exposure for enhanced therapeutic effect.
Approved indications
- Epilepsy (adjunctive therapy for partial seizures)
- Generalized tonic-clonic seizures
Common side effects
- Somnolence
- Ataxia
- Dizziness
- Anorexia
- Cognitive impairment
- Nephrolithiasis (kidney stones)
- Hypohidrosis (decreased sweating)
Key clinical trials
- Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma (PHASE1, PHASE2)
- Low and High Dose Zonisamide in Children as Monotherapy (PHASE4)
- Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- zonisamide high dose group CI brief — competitive landscape report
- zonisamide high dose group updates RSS · CI watch RSS
- Eisai Korea Inc. portfolio CI
Frequently asked questions about zonisamide high dose group
What is zonisamide high dose group?
How does zonisamide high dose group work?
What is zonisamide high dose group used for?
Who makes zonisamide high dose group?
What drug class is zonisamide high dose group in?
What development phase is zonisamide high dose group in?
What are the side effects of zonisamide high dose group?
What does zonisamide high dose group target?
Related
- Drug class: All Sulfonamide anticonvulsant drugs
- Target: All drugs targeting Voltage-gated sodium channels, T-type calcium channels, GABA enhancement
- Manufacturer: Eisai Korea Inc. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Epilepsy (adjunctive therapy for partial seizures)
- Indication: Drugs for Generalized tonic-clonic seizures
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing